Outcomes of interest in evidence-based evaluations of genetic tests

Genetics in Medicine

Volumn 12, Issue 4, 2010, Pages 228-235

  Botkin, Jeffrey R ^a   Teutsch, Steven M ^b   Kaye, Celia I ^c   Hayes, Maxine ^d   Haddow, James E ^e   Bradley, Linda A ^e,f   Szegda, Kathleen ^g   Dotson, W David ^f  

^a UNIVERSITY OF UTAH   (United States)

^b Los Angeles County Department of Public Health   (United States)

^c Children's Hospital Colorado   (United States)

^d WASHINGTON STATE DEPARTMENT OF HEALTH   (United States)

^e BROWN UNIVERSITY   (United States)

^f NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^g Baystate Children's Hospital   (United States)

Author keywords

Analytic validity; Clinical utility; Clinical validity; Expressivity; Genetic counseling; Genetic test; Molecular diagnostic techniques; Outcomes; Penetrance; Screening

Indexed keywords

CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; FAMILY; GENE TECHNOLOGY; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; MOLECULAR GENETICS; MORBIDITY; MORTALITY; PENETRANCE; REVIEW; SOCIAL PSYCHOLOGY; SOCIETY; VALIDITY;

EVIDENCE-BASED MEDICINE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; NATIONAL HEALTH PROGRAMS; OUTCOME ASSESSMENT (HEALTH CARE); RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 77951482885     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181cdde04     Document Type: Review

References (67)

1. Guttmacher AE, Collins FS. Welcome to the genomic era. N Engl J Med 2003;349:996-998.
2. Burke W, Psaty BM. Personalized medicine in the era of genomics. JAMA 2007;298:1682-1684. (Pubitemid 47606657)
3. GeneTests website. Available at: http://www.genetests.org/. Accessed March 20, 2009.
4. About EGAPP. Available at: http://www.egappreviews.org/about.htm, 2008. Accessed November 28, 2008.
5. Schmidt C. Regulators weigh risks of consumer genetic tests. Nat Biotech 2008;26:145-146. (Pubitemid 351225936)
6. Genetics and Public Policy Center. FDA Regulation of Genetic Tests, 2008. Available at:http://www.dnapolicy.org/images/issuebriefpdfs/FDA-Regulation- of-Genetic-Test-Issue-Brief.pdf. Accessed March 22, 2009.
7. U.S. System of Oversight of Genetic Testing. A Response to the Charge of the Secretary of Health and Human Services. Report of the Secretary's Advisory Committee on Genetics, Health, and Society, 2008. http://oba.od. nih.gov/oba/SACGHS/reports/reports/SACGHS-oversight-report.pdf. Accessed on January. 4, 2009.
8. Evaluation of Genomic Applications in Practice and Prevention. Available at: http://www.egappreviews.org/. Accessed March 22, 2009.
9. CDC Office of Public Health Genomics. About EGAPP. Available at: http://www.cdc.gov/genomics/gtesting/EGAPP/about.htm. Accessed March 22, 2009
10. What is the EGAPP Working Group? Available at: http://www.egappreviews. org/resources/faq.htm#working-what, 2008. Accessed November 19, 2008.
11. Collaboration Education and Test Translation Program. Available at: http://www.cettprogram.org/. Accessed November 19, 2008.
12. EGAPP Resources. Frequently asked questions, 2008; Available at: http://www.egappreviews.org/resources/faq.htm. Accessed March 22, 2009.
13. U.S. Preventive Services Task Force (USPSTF). Available at: http://www.ahrq. gov/clinic/USpstfix.htm. Accessed March 22, 2009.
14. The Cochrane Collaboration. Available at: http://www.cochrane.org/. Accessed March 22, 2009.
15. Health Technology Assessment International. Available at: http://www.htai. org/. Accessed March 22, 2009.
16. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009;11:3-14.
17. Haddow JE, Palomaki GE. ACCE: A model process for evaluating data on emerging genetic tests. In: Khoury MJ, Little J, Burke W, editors. Human genome epidemiology: a scientific foundation for using genetic information to improve health and prevent disease. New York: Oxford University Press, 2004:217-233.
18. CDC Office of Public Health Genomics.ACCE Project 2007://www.cdc.gov/ genomics/gTesting/ACCE.htm. Accessed March 22, 2009.
19. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001;20(suppl 3):21-35. (Pubitemid 33732964)
20. Sawaya GF, Guirguis-Blake J, LeFevre M, Harris R, Petitti D. Update on the methods of the U.S. Preventive Services Task Force: estimating certainty and magnitude of net benefit. Ann Intern Med 2007;147:871-875. (Pubitemid 351664424)
21. Tatsioni A, Zarin DA, Aronson N, et al. Challenges in systematic reviews of diagnostic technologies. Ann Intern Med 2005;142:1048-1055. (Pubitemid 40847707)
22. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med 2007;9:819-825.
23. Matchar DB, Thakur ME, Grossman I, et al. Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evid Rep Technol Assess (Full Rep) 2007;(146):1-77. (Pubitemid 350295210)
24. Friedman JM, Baross A, Delaney AD, et al. Oligonucleotide microarray analysis of genomic imbalance in children with mental retardation. Am J Hum Genet 2006;79:500-513. (Pubitemid 44384259)
25. Watson MS. Current status of newborn screening: decision-making about the conditions to include in screening programs. Ment Retard Dev Disabil Res Rev 2006;12:230-235.
26. Cummings S. The genetic testing process: how much counseling is needed? J Clin Oncol 2000;18(suppl 21):60S-64S.
27. Claes E, Evers-Kiebooms G, Denayer L, et al. Predictive genetic testing for hereditary breast and ovarian cancer: psychological distress and illness representations 1 year following disclosure. J Genet Couns 2005;14:349-363. (Pubitemid 41407042)
28. Hallowell N, Foster C, Ardern-Jones A, Eeles R, Murday V, Watson M. Genetic testing for women previously diagnosed with breast/ovarian cancer: examining the impact of BRCA1 and BRCA2 mutation searching. Genet Test 2002;6:79-87.
29. Schlich-Bakker KJ, ten Kroode HF, Ausems MG. A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Educ Couns 2006;62:13-20. (Pubitemid 43832070)
30. Aktan-Collan K, Haukkala A, Mecklin JP, Uutela A, Kaariainen H. Psychological consequences of predictive genetic testing for hereditary non-polyp-osis colorectal cancer (HNPCC): a prospective follow-up study. Int J Cancer 2001;93:608-611. (Pubitemid 32701422)
31. Beery TA, Williams JK. Risk reduction and health promotion behaviors following genetic testing for adult-onset disorders. Genet Test 2007;11: 111-123.
32. Collins V, Meiser B, Gaff C, St John DJ, Halliday J. Screening and preventive behaviors one year after predictive genetic testing for hereditary nonpolyposis colorectal carcinoma. Cancer 2005;104:273-281. (Pubitemid 40993253)
33. Decruyenaere M, Evers-Kiebooms G, Cloostermans T, et al. Psychological distress in the 5-year period after predictive testing for Huntington's disease. Eur J Hum Genet 2003;11:30-38. (Pubitemid 36175781)
34. Esplen MJ, Madlensky L, Butler K, et al. Motivations and psychosocial impact of genetic testing for HNPCC. Am J Med Genet 2001;103:9-15. (Pubitemid 32803092)
35. Gritz ER, Peterson SK, Vernon SW, et al. Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 2005;23: 1902-1910. (Pubitemid 46211368)
36. Meiser B, Collins V, Warren R, et al. Psychological impact of genetic testing for hereditary non-polyposis colorectal cancer. Clin Genet 2004;66:502-511. (Pubitemid 39562012)
37. van Oostrom I, Meijers-Heijboer H, Lodder LN, et al. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol 2003;21:3867-3874. (Pubitemid 46606243)
38. Vastag B. Cystic fibrosis gene testing a challenge: experts say widespread use is creating unnecessary risks. JAMA 2003;289:2923-2924. (Pubitemid 37430090)
39. Giardiello FM, Brensinger JD, Petersen GM, et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 1997;336:823-827. (Pubitemid 27132979)
40. Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008;359:2208-2219.
41. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008;359: 2220-2232.
42. Schulze MB, Weikert C, Pischon T, et al. Use of multiple metabolic and genetic markers to improve the prediction of type 2 diabetes: the EPIC-Potsdam Study. Diabetes Care 2009;32:2116-2119.
43. Szabo CI, Worley T, Monteiro AN. Understanding germ-line mutations in BRCA1. Cancer Biol Ther 2004;3:515-520. (Pubitemid 41351120)
44. van Dijk S, van Asperen CJ, Jacobi CE, et al. Variants of uncertain clinical significance as a result of BRCA1/2 testing: impact of an ambiguous breast cancer risk message. Genet Test 2004;8:235-239. (Pubitemid 39586791)
45. Green MJ, Botkin JR. "Genetic exceptionalism" in medicine: clarifying the differences between genetic and nongenetic tests. Ann Intern Med 2003;138: 571-575.
46. Applebaum-Shapiro SE, Peters JA, O'Connell JA, Aston CE, Whitcomb DC. Motivations and concerns of patients with access to genetic testing for hereditary pancreatitis. Am J Gastroenterol 2001;96:1610-1617.
47. Fulda KG, Lykens K. Ethical issues in predictive genetic testing: a public health perspective. J Med Ethics 2006;32:143-147. (Pubitemid 43338117)
48. Peterson EA, Milliron KJ, Lewis KE, Goold SD, Merajver SD. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 2002;11:79-87.
49. Shinaman A, Bain LJ, Shoulson I. Preempting genetic discrimination and assaults on privacy: report of a symposium. Am J Med Genet A 2003;120A: 589-593. (Pubitemid 37063761)
50. Hudson KL, Holohan MK, Collins FS. Keeping pace with the times\the Genetic Information Nondiscrimination Act of 2008. N Engl J Med 2008; 358:2661-2663.
51. Kefford R, Bishop JN, Tucker M, et al. Genetic testing for melanoma. Lancet Oncol 2002;3:653-654. (Pubitemid 35314906)
52. Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999;17:3245-3251. (Pubitemid 29470659)
53. Fraenkel L, McGraw S. What are the essential elements to enable patient participation in medical decision making? J Gen Intern Med 2007;22:614-619. (Pubitemid 46941190)
54. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997;277:997-1003. (Pubitemid 27142370)
55. Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 2003;53:141-169. (Pubitemid 36722306)
56. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89. (Pubitemid 46535708)
57. Bradbury A, Olopade OI. The case for individualized screening recommendations for breast cancer. J Clin Oncol 2006;24:3328-3330. (Pubitemid 46638884)
58. National Cancer Institute. Genetic testing for BRCA1 and BRCA2: it's your choice, 2002. Available at: http://www.cancer.gov/cancertopics/factsheet/risk/ brca. Accessed March 22, 2009.
59. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003;348: 2339-2347. (Pubitemid 36638109)
60. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005;143: 355-361.
61. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35-41.
62. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009;11:42-65.
63. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
64. Sutton VR. Tay-Sachs disease screening and counseling families at risk for metabolic disease. Obstet Gynecol Clin North Am 2002;29:287-296.
65. Burke W, Khoury MJ, Stewart A, Zimmern RL. The path from genome-based research to population health: development of an international public health genomics network. Genet Med 2006;8:451-458. (Pubitemid 44289008)
66. Holtzman NA, Marteau TM. Will genetics revolutionize medicine? N Engl J Med 2000;343:141-144.
67. Sankar P, Cho MK, Condit CM, et al. Genetic research and health disparities. JAMA 2004;291:2985-2989. (Pubitemid 38802688)